Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AVEO Pharmaceuticals, Inc.
NRG Oncology
AstraZeneca
Johnson & Johnson Enterprise Innovation Inc.
Eastern Cooperative Oncology Group
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Brown University
Incyte Corporation
Centre Leon Berard
Merck Sharp & Dohme LLC
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Bristol-Myers Squibb
Shanghai Miracogen Inc.
Bristol-Myers Squibb
Radiation Therapy Oncology Group
Merck KGaA, Darmstadt, Germany
AstraZeneca
Bristol-Myers Squibb
Lund University Hospital
Arbeitsgemeinschaft medikamentoese Tumortherapie
Groupe Oncologie Radiotherapie Tete et Cou
Incyte Corporation
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Bristol-Myers Squibb
Gruppo Oncologico del Nord-Ovest
University of Warwick
Sun Yat-sen University
Merck KGaA, Darmstadt, Germany
Associazione Volontari Pazienti Oncologici
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
University of Alabama at Birmingham